A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Summary

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• ER+, HER 2- Breast Cancer
• Non-small Cell Lung Cancer (NSCLC)
• Castration-resistant Prostate Cancer (CRPC)
• Microsatellite Stable (MSS) Colorectal Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 99 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

IDEAYA Biosciences

Last updated on ClinicalTrials.gov

June 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites